Collegium Pharma
Last updated Jun 26, 2026
Evidence Sources
2
Competitive Findings
0
Portfolio Developments
0
Regulatory Precedents
8
Clinical Programs
0
Confidence Coverage
67%
Audit
- Competitor findings: 0
- Portfolio developments: 0
- Self-competition findings removed: 0
- Unknown ownership findings removed: 0
Executive Summary
Material intelligence activity detected across:
- Pain Management
- Opioid
Highest priority development: FDA approves sacituzumab govitecan-hziy as monotherapy and in combination with pembrolizumab for first-line treatment of triple-negative breast cancer
Regulatory precedent
Why this matters: sets a safety guidance precedent in the same sub-indication (pain) as Collegium Pharma; the same agency is already in play for this signal, so precedent weight is higher.
Competitive pressure: Low
Portfolio impact: High
Evidence coverage: 67%
Active Signals
3
Investigate Priority
0
Opportunity Score
58
Buyer Quality
7 · Emerging
Recent Signals
Latest intelligence events linked to this organization.
- MonitorJun 26, 2026Score 20FDA Approves Supplement for XTAMPZA ER by Collegium Pharma
Pain Management · Opioid
- MonitorJun 26, 2026Score 19FDA Acceptance of NUCYNTA ER Supplement Application by Collegium Pharma
Pain Management · Opioid
- MonitorJun 26, 2026Score 19FDA Accepts Supplement Application for NUCYNTA (Tapentadol Hydrochloride)
Pain Management · Opioid
Related Assets
Portfolio asset pages with evidence-based assessments.
No linked asset pages are available yet.
Portfolio Development
Owned-asset pipeline events — Phase III readouts, approvals, label expansions, and deals. Not classified as competitive threats.
No portfolio development items are linked to this company yet.
Competitive Intelligence Findings
Competitiva findings with evidence, reasoning, and confidence calibration.
No Competitiva findings are linked to this company yet.
Regulatory Developments
Regunera precedents with source attribution and confidence disclosure.
- FDA approves sacituzumab govitecan-hziy as monotherapy and in combination with pembrolizumab for first-line treatment of triple-negative breast cancerModerate Confidence · 66%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera - Quantitative Systems Pharmacology (QSP)-Based Dose Selection for Minimum Anticipated Biological Effect Level (MABEL) in First-in-Human (FIH) TrialsModerate Confidence · 66%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera - FDA AP — XTAMPZA ER (SUPPL)Moderate Confidence · 66%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera - FDA AP — XTAMPZA ER (SUPPL)Moderate Confidence · 66%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera
Clinical Developments
Pipeline activity with auditable evidence and uncertainty disclosure.
No clinical developments are linked yet.
Investigate-Priority Items
Signals flagged for investigation or escalation — highest urgency for portfolio review.
No investigate-priority signals are active for this company.
Humanexa Agent Questions
Suggested prompts to explore this organization's intelligence profile. Open a linked signal to ask the agent.
- What are the most material competitive threats to Collegium Pharma right now?
- Which regulatory precedents should Collegium Pharma monitor in Pain Management and Opioid?
- Which pipeline programs should Collegium Pharma prioritize for competitive review?
- What signals require immediate investigation for Collegium Pharma?
- Summarize the strategic implications of recent developments for Collegium Pharma.
- Where is the greatest uncertainty in Collegium Pharma's competitive positioning?